JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  05/20 04:00:02 pm EDT
176.98 USD   +1.75%
05/20DOJ Objects to Cost of J&J Talc Unit Hiring Katyal For Appeal
DJ
05/20Top Midday Gainers
MT
05/20Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & Johnson Unit's Trabectedin in Mice Study
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CDC: Vaccines less effective against Omicron, but still reduce risk for serious illness

01/21/2022 | 01:21pm EDT

The COVID-19 vaccines currently available in the United States were less effective at preventing against infection after the Omicron variant of the virus emerged in November, according to data released Friday by the Centers for Disease Control and Prevention.

However, they still lower the risk for serious illness among those who are fully vaccinated, as well as those who have received booster doses, according to the agency.

In October and November, when the Delta variant was still the predominant one in circulation nationally, the shots available from Johnson & Johnson, Moderna and Pfizer-BioNTech, collectively, offered 93% protection against infection, the data showed.

By December, though, when the Omicron strain accounted for more than 70% of new cases across the country, vaccine effectiveness dipped to 80%, the agency said.

Still, through the end of November, the unvaccinated made up 75% of all reported COVID-19 deaths across the 22 states and three metropolitan areas -- New York City, Seattle and Washington, D.C. -- included in the analysis, according to the CDC.

The vaccine effectiveness figures are based on infection rates among those fully vaccinated, meaning they had received both doses of the Moderna and Pfizer-BioNTech shots or the single-dose Johnson & Johnson product, the CDC said.

A booster dose of all three vaccines increased effectiveness at protecting against infection to 82%, a separate analysis, also released Friday, found.

"COVID-19 vaccines reduced risks for ... infection and COVID-19-associated death during periods of Delta variant predominance and infection risk during Omicron variant emergence, the CDC researchers wrote.

"Because of reporting lags, the influence of the Omicron variant on COVID-19-associated deaths by vaccination status in December could not be evaluated," they said.

The Omicron variant of COVID-19 is believed to be more contagious and resistant to currently available vaccines, experts said.

As a result of the reduced effectiveness of the vaccines at preventing infection with Omicron, the regions included in the analysis reported a 23% increase in new cases among those fully vaccinated after the strain emerged, according to the agency.

Case figures also increased six-fold among those fully vaccinated and boostered, the agency said.

However, after the emergence of Omicron, the unvaccinated were four times as likely to be hospitalized due to COVID-19 than those who were within six months of becoming fully vaccinated, the data showed.

They were also 25% more likely to require hospital treatment following infection than those who were more than six months out from the final vaccine dose and twice as likely to be hospitalized than those who had received a booster, according to the CDC.

Even with Omicron, the vaccines were 90% effective at preventing severe illness, as measured by hospitalizations, the agency said.

"These findings underscore the importance of receiving a third dose of [the Moderna or Pfizer-BioNTech vaccines] to prevent both moderately severe and severe COVID-19, especially while the Omicron variant is the predominant circulating variant," the CDC researchers wrote.

"All unvaccinated persons should get vaccinated as soon as possible," they added.

Copyright 2022 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source Health News - Business

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 1.75% 176.98 Delayed Quote.1.68%
MODERNA, INC. -4.97% 136.25 Delayed Quote.-46.35%
All news about JOHNSON & JOHNSON
05/20DOJ Objects to Cost of J&J Talc Unit Hiring Katyal For Appeal
DJ
05/20Top Midday Gainers
MT
05/20Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & J..
MT
05/19The Janssen Pharmaceutical Companies - New Data Show TREMFYA (guselkumab) Binds to Both..
AQ
05/19New Janssen Campaign Developed by and for the LGBTQ+ Community Inspires Action and Empa..
AQ
05/18Thinking about trading options or stock in Costco, Dollar Tree, Micron, Upstart, or Joh..
PR
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
05/17Citigroup Adjusts Price Target on Johnson & Johnson to $205 From $210, Reiterates Buy R..
MT
05/16Mariners put RHP Steckenrider on restricted list, add Elías
AQ
05/13Idaho announces $119 million opioid crisis settlement
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 96 248 M - -
Net income 2022 23 016 M - -
Net cash 2022 8 885 M - -
P/E ratio 2022 19,9x
Yield 2022 2,52%
Capitalization 466 B 466 B -
EV / Sales 2022 4,75x
EV / Sales 2023 4,51x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 176,98 $
Average target price 186,82 $
Spread / Average Target 5,56%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.68%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707
NOVO NORDISK A/S3.58%245 099